Pulmonary Drugs Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

 

Pulmonary Drugs Market
Pulmonary Drugs Market

The pulmonary drugs market is a significant part of the pharmaceutical industry, with a global market size projected to reach USD 60.1 billion by 2026, according to a report by Grand View Research. This market comprises drugs used in the treatment of respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), and cystic fibrosis. The increasing prevalence of these diseases, coupled with the rising geriatric population, is expected to drive the growth of this market in the coming years.

Asthma is a chronic respiratory disease that affects the airways in the lungs, causing them to narrow and making it difficult to breathe. According to the World Health Organization, asthma affects around 235 million people worldwide. The treatment of asthma primarily involves the use of inhaled corticosteroids, which reduce inflammation in the airways, and bronchodilators, which relax the muscles around the airways. The Pulmonary Drugs Market was valued at USD 22.2 billion in 2020, according to a report by Market Research Future.

COPD is a group of lung diseases that cause breathing difficulties, including chronic bronchitis and emphysema. The primary cause of COPD is smoking, but it can also be caused by exposure to air pollution, dust, and chemicals. According to the Global Initiative for Chronic Obstructive Lung Disease, COPD is the third leading cause of death worldwide Pulmonary Drugs Market, with over 251 million cases reported in 2016. The treatment of COPD involves the use of bronchodilators, corticosteroids, and antibiotics. The global market for COPD drugs was valued at USD 14.5 billion in 2020.

PAH is a rare but severe condition that affects the blood vessels in the lungs, causing high blood pressure in the pulmonary arteries. PAH can lead to heart failure if left untreated. The primary cause of PAH is unknown, but it can be associated with other conditions such as connective tissue diseases and congenital heart disease. The treatment of PAH involves the use of vasodilators, which relax the blood vessels in the lungs, and endothelin receptor antagonists, which block the action of endothelin, a peptide that causes blood vessels to constrict. The global market for PAH drugs was valued at USD 6.9 billion in 2020.

Comments

Popular posts from this blog

The Role of the Foodservice Industry in Driving the French Fries Market

Market Share and Revenue Analysis of the Microdermabrasion Devices Market

The Growing Demand for Healthcare Staffing Market: Trends and Opportunities